WALTHAM, Mass.–(BUSINESS WIRE)– #ClinicalTrials–Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the company’s clinical trial application for PX578, the company’s lead therapeutic candidate being developed for
